Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Acoramidis cuts all-cause and cardiovascular death risk in ATTR-CM patients by nearly half through 54 months.
BBIO
$82.33
-$1.77 -2.10%

Acoramidis cuts all-cause and cardiovascular death risk in ATTR-CM patients by nearly half through 54 months.

Company Fundamentals
30 Mar 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

BridgeBio Pharma presented long-term data showing acoramidis significantly reduces all-cause mortality by 44.7% and cardiovascular mortality by 49.3% in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) through 54 months. The drug also stabilizes heart failure symptoms and biomarkers, improving quality of life with a strong safety profile. These results highlight the importance of early and continuous treatment for sustained benefits in this serious heart condition. Acoramidis is approved in the US and Europe, with more data expected in future medical meetings.

More News (BBIO)

BridgeBio Pharma stays a strong buy with key drug approvals and $1B funding boost.

BridgeBio Pharma stays a strong buy with key drug approvals and $1B funding boost.

BridgeBio Pharma remains a strong buy due to regulatory approvals for its drug acoramidis and positive clinical data for infigratinib in achondroplasia. The company expects $180.6 million in U.S. net product revenue by Q1 2026 and targets a $2.9 bill...

Analyst Insights
Bullish
3 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App